Back to Search

A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients With Advanced Solid Tumors

  • Protocol Number: 202103029
  • Principal Investigator: Morgensztern, Daniel
  • Cancer Types: Early Phase, Lung

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.

Protocol Interventions

JAB-3312, Binimetinib, Pembrolizumab, Sotorasib, Osimertinib